BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/12/2020 9:10:19 AM | Browse: 798 | Download: 1455
 |
Received |
|
2020-05-12 10:50 |
|
Peer-Review Started |
|
2020-05-12 10:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-06-15 18:38 |
|
Revised |
|
2020-06-20 13:53 |
|
Second Decision |
|
2020-07-21 09:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-07-26 21:40 |
|
Articles in Press |
|
2020-07-26 21:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-03 02:33 |
|
Typeset the Manuscript |
|
2020-08-10 06:02 |
|
Publish the Manuscript Online |
|
2020-08-12 09:10 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Yan, Hong-Wei Lin, Zhuo-Nan Zhuang, Ming Li and Sen Guo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Tsinghua Changgung Hospital Fund |
12015C1042 |
| Bethune-Excellent Surgery Fund |
HZB-20181119-13 |
| Chen Xiaoping Science and Technology Development Fund |
CXPJH11800004-021 |
|
| Corresponding Author |
Sen Guo, PhD, Adjunct Professor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107, Wenhuaxi Street, Jinan 250033, Shandong Province, China. guosen4321@163.com |
| Key Words |
Colon carcinoma; Chemotherapy; Nuclear factor kappa-B; Interleukin-1; Proliferation; Fluorouracil |
| Core Tip |
There was the feedback loop between up-regulated nuclear factor kappa-B (NF-κB) pathway and interleukin (IL)-1 which lead to the proliferation of cancer cells. Fluorouracil (5-FU), as a chemotherapy drug used to treat colon carcinoma cells, can activate the NF-κB pathway and lead to the resistance of chemotherapy. IL-1 receptor antagonist combined with 5-FU has stronger inhibitory effect on the proliferation of colon cancer cells due to the blocking of IL-1. It could provide an adjuvant chemotherapy plan for clinic and provide a theoretical basis for neoadjuvant chemotherapy. |
| Publish Date |
2020-08-12 09:10 |
| Citation |
Yan Y, Lin HW, Zhuang ZN, Li M, Guo S. Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer. World J Gastrointest Oncol 2020; 12(8): 877-892 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i8/877.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i8.877 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
